Scott Burrows Net Worth

The estimated Net Worth of Scott L Burrows is at least $920 mil dollars as of 6 March 2023. Mr. Burrows owns over 291 units of Arcutis Biotherapeutics Inc stock worth over $621,890 and over the last 4 years he sold ARQT stock worth over $298,495. In addition, he makes $0 as Vice President - Finance at Arcutis Biotherapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Burrows ARQT stock SEC Form 4 insiders trading

Scott has made over 6 trades of the Arcutis Biotherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 291 units of ARQT stock worth $4,441 on 6 March 2023.

The largest trade he's ever made was selling 12,560 units of Arcutis Biotherapeutics Inc stock on 27 December 2021 worth over $252,079. On average, Scott trades about 2,042 units every 43 days since 2021. As of 6 March 2023 he still owns at least 59,115 units of Arcutis Biotherapeutics Inc stock.

You can see the complete history of Mr. Burrows stock trades at the bottom of the page.

Scott Burrows biography

Scott L. Burrows serves as Vice President - Finance of the Company. From March 2018 to May 2019, he was the Head of International Investor Relations for Shire Plc in Zug, Switzerland. Prior to that, Mr. Burrows spent 15 years at Amgen in various Finance roles of increasing responsibility, including Financial Planning & Analysis, Treasury, and Investor Relations. Mr. Burrows started his career as a management consultant with Arthur Andersen in Los Angeles. He received both a B.A. in Business Economics and an M.B.A. from the University of California, Los Angeles and is a Certified Public Accountant (inactive).

How old is Scott Burrows?

Scott Burrows is 42, he's been the Vice President - Finance of Arcutis Biotherapeutics Inc since 2019. There are 26 older and 2 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.

What's Scott Burrows's mailing address?

Scott's mailing address filed with the SEC is 221 CRESCENT STREET, BUILDING, 23, SUITE 105, WALTHAM, MA, 02453.

Insiders trading at Arcutis Biotherapeutics Inc

Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron, eAdvisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.

What does Arcutis Biotherapeutics Inc do?

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Complete history of Mr. Burrows stock trades at Aeglea BioTherapeutics Inc e Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc executives and stock owners

Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Watanabe,
  President, Chief Executive Officer, Director
• Kenneth Lock,
  Chief Commercial Officer
• Todd Franklin Watanabe M.A.,
  Pres, CEO & Director
• Patricia Turney,
  Senior Vice President - Manufacturing
• Dr. Patrick E. Burnett M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kenneth A. Lock,
  Chief Commercial Officer
• Bhaskar Chaudhuri,
  Independent Director
• Joseph Turner,
  Independent Director
• Ricky Sun,
  Independent Director
• Jonathan Silverstein,
  Independent Director
• Howard Welgus,
  Director
• Halley Gilbert,
  Director
• Terrie Curran,
  Director
• Patrick Burnett,
  Chief Medical Officer
• Keith Klein,
  General Counsel
• Frank Pompilio,
  Vice President - Medical Affairs
• Lynn Navale,
  Vice President - Biometrics
• Charlotte Merritt,
  Vice President - Regulatory Affairs
• Ayisha Jeter,
  Vice President of Market Access
• Meg Elias,
  Vice President - Clinical Operations
• Bethany Dudek,
  Vice President - Quality
• David Berk,
  Vice President - Clinical Development
• Heather Armstrong,
  Vice President of Investor Relations and Corporate Communications
• Kimberly Lathroum,
  Vice President of Marketing
• Jay Ramsinghani,
  Vice President of Commercial Strategy and Operations
• Scott Burrows,
  Vice President - Finance
• John Smither,
  Chief Financial Officer
• David Osborne,
  Co-Founder, Chief Technical Officer
• Patrick Heron,
  Independent Chairman of the Board
• Masaru Matsuda Esq., J.D.,
  Gen. Counsel & Corp. Sec.
• Courtney Barton,
  Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
• Eric McIntyre,
  Head of Investor Relations
• Dr. David W. Osborne,
  Chief Technical Officer
• Patricia A. Turney,
  Sr. VP of Operations
• Scott L. Burrows,
  CFO & Principal Accounting Officer
• Larry Todd Edwards,
  SVP Chief Commercial Officer
• Daniel Estes,
  Director
• Neha Krishnamohan,
  Director
• David Joseph Topper,
  Chief Financial Officer
• Masaru Matsuda,
  See Remarks
• Capital Life Sciences Inves...,
  
• Advisors Llcorbimed Capital...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Matthew Richard Moore,
  SVP and Chief Business Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Sue Jean Lin,
  Director
• Keith R Leonard,
  Director
• Life Sciences Viii, L.P.Fhm...,